Thermo Scientific™ Sensititre Custom Plates
Thermo Scientific™ Sensititre Custom Plates offer custom MIC frozen plates to support clinical drug trials for FDA submissions, custom plate/ancilliaries for new compound development and surveillance testing, and comparative validation studies.
Receive your quote directly from the manufacturer.
Thermo Scientific™ Sensititre Custom Plates offer custom MIC frozen plates to support clinical drug trials for FDA submissions, custom plate/ancilliaries for new compound development and surveillance testing, and comparative validation studies.
Through collaboration with all major pharmaceutical companies, the Sensititre System offers an extensive range of antimicrobics available for user-defined custom plates.
- A selection from over 240 antimicrobics can be incorporated into custom formats configured to meet testing requirements
- Antimicrobic selections are provided for both full range MIC and Breakpoint testing procedures
- To meet individual laboratory test requirements, custom susceptibility plates are available in dry format and in frozen format, manufactured to meet FDA, CLSI or EUCAST guidelines
- Small minimum order quantities allow for better cost and inventory control
CLINICAL24: Carbapenem resistance in 2026: From rapid detection to actionable susceptibility results
Monday, November 30 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST
From resistance detection to actionable AST: Navigating the changing landscape of Gram-negative resistance.
Antimicrobial resistance among Gram-negative organisms continues to present significant challenges for clinical microbiology laboratories. As resistance mechanisms evolve and new antimicrobial therapies become available, laboratories need to consider how best to translate resistance detection into clinically relevant antimicrobial susceptibility results.
Join Professor Laurent Dortet and Professor Axel Hamprecht, internationally recognized experts in antimicrobial resistance and clinical microbiology, for a practical discussion on the evolving landscape of Gram-negative resistance and its implications for antimicrobial susceptibility testing (AST).
The speakers will explore current and emerging resistance mechanisms, including carbapenem resistance, and discuss what resistance-mechanism detection can—and cannot—tell the laboratory. They will examine the complementary role of phenotypic AST and MIC determination, particularly when managing challenging multidrug-resistant organisms and newer antimicrobial treatment options.
Through practical examples and case-based discussion, the webinar will also consider how laboratories can adapt their AST strategies as resistance patterns, antimicrobial formularies, and breakpoint requirements evolve.
The session will conclude with an expert discussion and live Q&A, providing attendees with an opportunity to put their questions directly to Professors Dortet and Hamprecht.
Register to explore how the clinical microbiology laboratory can move from identifying resistance to generating actionable susceptibility information in an increasingly complex Gram-negative landscape.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
- Format: Expert presentation followed by live Q&A
Can't attend live?
Register today and you will receive access to the recording after the webinar, allowing you to revisit key insights and share learning across your team.
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Certificate of attendance
All attendees who join the live webinar will automatically receive a certificate of attendance, including a summary of key learning outcomes, to support their continuing professional development.
If you watch the on-demand recording, a certificate of attendance can be requested by emailing editor@selectscience.net.
About CLINICAL24
CLINICAL24 is a global initiative dedicated to exploring the challenges facing modern clinical laboratories and highlighting the technologies, expertise, and collaborative approaches helping to improve patient care worldwide.
Oxoid Remel Microbiology innovates to combat AMR with advanced antimicrobial susceptibility testing
In this video, experts from Oxoid Remel Microbiology share how innovation in antimicrobial susceptibility testing (AST) is helping laboratories respond to the accelerating global challenge of antimicrobial resistance (AMR).
Speaking from a scientific and R&D perspective, Jeroen Bursens, Scientific Affairs Manager, and Jani Holopainen, Head of R&D for Microbiology, discuss how continuous panel updates, close collaboration with pharmaceutical developers, and direct engagement with customers ensure that Sensititre® broth microdilution testing remains clinically relevant in an evolving resistance landscape.
The conversation highlights emerging Gram-negative resistance mechanisms, including metallo‑β‑lactamases and carbapenem-resistant Acinetobacter baumannii, and the importance of incorporating novel antibiotics, such as aztreonam/avibactam and sulbactam/durlobactam, alongside broad, well-balanced panels to support optimal treatment decisions.
Looking ahead, the team outlines how automation, data integration, customization, and academic collaboration are shaping the future of Sensititre®, reinforcing the laboratory’s critical role in antimicrobial stewardship and the global fight against AMR.
Interview recorded at ESCMID Global 2026.
Please note: This video was recorded when the speakers represented Thermo Fisher Scientific. Following a subsequent acquisition, the updated content is now hosted under the Oxoid Remel Microbiology company page.
